If Astellas Pharmaceutical successfully acquires OCATA they would own all of OCATA's technology, patents, intellectual property, etc.
So, wouldn't taking your $8.50 per share after the acquisition and buying Astellas stock be prudent if OCATA really has a valid treatment that shows improvement for AMD/SMD?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.